Bravecto

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

fluralaner

Available from:

Intervet International B.V

ATC code:

QP53BE02

INN (International Name):

fluralaner

Therapeutic group:

Dogs; Cats

Therapeutic area:

Ectoparasiticides fyrir almenn nota, Isoxazolines

Therapeutic indications:

Hundar:- Fyrir meðferð merkið og fló sníkjudýra;varan er hægt að nota eins og hluti af meðferð áætlun til að stjórna fló ofnæmi exem (TÍSKA). - Fyrir meðferð demodicosis af völdum Demodex canis;- Fyrir meðferð sarcoptic girl (Sarcoptes scabiei var. canis) árás. - For reduction of the risk of infection with Babesia canis canis via transmission by Dermacentor reticulatus. [chewable tablets only]Cats:- For the treatment of tick and flea infestations;The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). - Fyrir meðferð sníkjudýra með eyra maurum (Otodectes cynotis).

Product summary:

Revision: 17

Authorization status:

Leyfilegt

Authorization date:

2014-02-11

Patient Information leaflet

                                40
B. FYLGISEÐILL
41
FYLGISEÐILL:
BRAVECTO 112,5 MG TUGGUTÖFLUR FYRIR MJÖG LITLA HUNDA (2-4,5 KG)
BRAVECTO 250 MG TUGGUTÖFLUR FYRIR LITLA HUNDA (>4,5-10 KG)
BRAVECTO 500 MG TUGGUTÖFLUR FYRIR MEÐALSTÓRA HUNDA (>10-20 KG)
BRAVECTO 1.000 MG TUGGUTÖFLUR FYRIR STÓRA HUNDA (>20-40 KG)
BRAVECTO 1.400 MG TUGGUTÖFLUR FYRIR MJÖG STÓRA HUNDA (>40-56 KG)
1.
HEITI OG HEIMILISFANG MARKAÐSLEYFISHAFA OG ÞESS FRAMLEIÐANDA
SEM BER ÁBYRGÐ Á LOKASAMÞYKKT, EF ANNAR
Markaðsleyfishafi og framleiðandi sem ber ábyrgð á lokasamþykkt:
Intervet International B. V.
Wim de Körverstraat 35
5831 AN Boxmeer
Holland
Framleiðandi sem ber ábyrgð á lokasamþykkt:
Intervet GesmbH
Siemensstrasse 107
1210 Vienna
Austurríki
2.
HEITI DÝRALYFS
Bravecto 112,5 mg tuggutöflur fyrir mjög litla hunda (2 - 4,5 kg)
Bravecto 250 mg tuggutöflur fyrir litla hunda (>4,5 - 10 kg)
Bravecto 500 mg tuggutöflur fyrir meðalstóra hunda (>10
-
20 kg)
Bravecto 1.000 mg tuggutöflur fyrir stóra hunda (>20 - 40 kg)
Bravecto 1.400 mg tuggutöflur fyrir mjög stóra hunda (>40 - 56 kg)
fluralaner
3.
VIRK(T) INNIHALDSEFNI OG ÖNNUR INNIHALDSEFNI
Hver tuggutafla inniheldur:
BRAVECTO TUGGUTÖFLUR
FLURALANER (MG)
fyrir mjög litla hunda (2 - 4,5 kg)
112,5
fyrir litla hunda (>4,5 - 10 kg)
250
fyrir meðalstóra hunda (>10 - 20 kg)
500
fyrir stóra hunda (>20 - 40 kg)
1.000
fyrir mjög stóra hunda (>40 - 56 kg)
1.400
Ljós- til dökkbrún hringlaga tafla með sléttu eða örlítið
hrjúfu yfirborði. Svolitlar yrjur, flekkir eða
hvort tveggja getur verið sýnilegt.
4.
ÁBENDING(AR)
Til meðferðar á mítla og flóasmiti hjá hundum.
Þetta dýralyf er skordýra- og mítlaeitur til altækrar verkunar
sem veitir:
-
tafarlausa og langvarandi flóadrepandi (
_Ctenophalides felis_
) verkun í 12 vikur,
42
-
tafarlausa og langvarandi mítladrepandi verkun í 12 vikur fyrir
_Ixodes ricinus, Dermacentor _
_reticulatus _
og
_ D. variabilis_
.,
-
tafarlausa og langvarandi mítladrepandi verkun í 8 vikur fyrir
_Rhipicephalus sanguineus_
Flærnar og 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
2
1.
HEITI DÝRALYFS
Bravecto 112,5 mg tuggutöflur fyrir mjög litla hunda (2 - 4,5 kg)
Bravecto 250 mg tuggutöflur fyrir litla hunda (>4,5 - 10 kg)
Bravecto 500 mg tuggutöflur fyrir meðalstóra hunda (>10 - 20 kg)
Bravecto 1.000 mg tuggutöflur fyrir stóra hunda (>20 - 40 kg)
Bravecto 1.400 mg tuggutöflur fyrir mjög stóra hunda (>40 - 56 kg)
2.
INNIHALDSLÝSING
VIRK INNIHALDSEFNI:
Hver tuggutafla inniheldur:
BRAVECTO TUGGUTÖFLUR
FLURALANER (MG)
fyrir mjög litla hunda (2 - 4,5 kg)
112,5
fyrir litla hunda (>4,5 - 10 kg)
250
fyrir meðalstóra hunda (>10 - 20 kg)
500
fyrir stóra hunda (>20 - 40 kg)
1.000
fyrir mjög stóra hunda (>40 - 56 kg)
1.400
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Tuggutafla.
Ljós- til dökkbrún hringlaga tafla með sléttu eða örlítið
hrjúfu yfirborði. Svolitlar yrjur, flekkir eða
hvort tveggja getur verið sýnilegt.
4.
KLÍNÍSKAR UPPLÝSINGAR
4.1
DÝRATEGUNDIR
Hundar
4.2
ÁBENDINGAR FYRIR TILGREINDAR DÝRATEGUNDIR
Til meðferðar á mítla og flóasmiti hjá hundum.
Þetta dýralyf er skordýra- og mítlaeitur til altækrar verkunar
sem veitir:
-
tafarlausa og langvarandi flóadrepandi (
_Ctenophalides felis_
) verkun í 12 vikur,
-
tafarlausa og langvarandi mítladrepandi verkun í 12 vikur fyrir
_Ixodes ricinus, Dermacentor _
_reticulatus _
og
_ D. variabilis_
,
-
tafarlausa og langvarandi mítladrepandi verkun í 8 vikur (
_Rhipicephalus sanguineus_
).
Flærnar og mítlarnir verða að festa sig við hýsil og byrja að
nærast til þess að verða útsett fyrir virka
efninu.
Lyfið má nota sem hluta af meðferðaráætlun til að hafa hemil á
ofnæmishúðbólgu vegna flóabits (flea
allergy dermatitis (FAD)).
Meðferð við hársekkjamaurakláða af völdum
_Demodex canis_
.
Meðferð við hundakláða smiti (
_Sarcoptes scabiei_
var.
_canis_
).
3
Til að draga úr hættu á sýkingu vegna
_Babesia canis canis_
með smiti frá
_Dermacentor reticulatus_
í allt
að 12 vikur. Áhrifin eru óbein 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 21-03-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 21-03-2022
Public Assessment Report Public Assessment Report Bulgarian 21-03-2022
Patient Information leaflet Patient Information leaflet Spanish 21-03-2022
Public Assessment Report Public Assessment Report Spanish 21-03-2022
Patient Information leaflet Patient Information leaflet Czech 21-03-2022
Public Assessment Report Public Assessment Report Czech 21-03-2022
Patient Information leaflet Patient Information leaflet Danish 21-03-2022
Public Assessment Report Public Assessment Report Danish 21-03-2022
Patient Information leaflet Patient Information leaflet German 21-03-2022
Public Assessment Report Public Assessment Report German 21-03-2022
Patient Information leaflet Patient Information leaflet Estonian 21-03-2022
Public Assessment Report Public Assessment Report Estonian 21-03-2022
Patient Information leaflet Patient Information leaflet Greek 21-03-2022
Public Assessment Report Public Assessment Report Greek 21-03-2022
Patient Information leaflet Patient Information leaflet English 21-03-2022
Public Assessment Report Public Assessment Report English 21-03-2022
Patient Information leaflet Patient Information leaflet French 21-03-2022
Public Assessment Report Public Assessment Report French 21-03-2022
Patient Information leaflet Patient Information leaflet Italian 21-03-2022
Public Assessment Report Public Assessment Report Italian 21-03-2022
Patient Information leaflet Patient Information leaflet Latvian 21-03-2022
Public Assessment Report Public Assessment Report Latvian 21-03-2022
Patient Information leaflet Patient Information leaflet Lithuanian 21-03-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-03-2022
Public Assessment Report Public Assessment Report Lithuanian 21-03-2022
Patient Information leaflet Patient Information leaflet Hungarian 21-03-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 21-03-2022
Public Assessment Report Public Assessment Report Hungarian 21-03-2022
Patient Information leaflet Patient Information leaflet Maltese 21-03-2022
Public Assessment Report Public Assessment Report Maltese 21-03-2022
Patient Information leaflet Patient Information leaflet Dutch 21-03-2022
Public Assessment Report Public Assessment Report Dutch 21-03-2022
Patient Information leaflet Patient Information leaflet Polish 21-03-2022
Public Assessment Report Public Assessment Report Polish 21-03-2022
Patient Information leaflet Patient Information leaflet Portuguese 21-03-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 21-03-2022
Public Assessment Report Public Assessment Report Portuguese 21-03-2022
Patient Information leaflet Patient Information leaflet Romanian 21-03-2022
Public Assessment Report Public Assessment Report Romanian 21-03-2022
Patient Information leaflet Patient Information leaflet Slovak 21-03-2022
Public Assessment Report Public Assessment Report Slovak 21-03-2022
Patient Information leaflet Patient Information leaflet Slovenian 21-03-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 21-03-2022
Public Assessment Report Public Assessment Report Slovenian 21-03-2022
Patient Information leaflet Patient Information leaflet Finnish 21-03-2022
Public Assessment Report Public Assessment Report Finnish 21-03-2022
Patient Information leaflet Patient Information leaflet Swedish 21-03-2022
Public Assessment Report Public Assessment Report Swedish 21-03-2022
Patient Information leaflet Patient Information leaflet Norwegian 21-03-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 21-03-2022
Patient Information leaflet Patient Information leaflet Croatian 21-03-2022
Public Assessment Report Public Assessment Report Croatian 21-03-2022

Search alerts related to this product

View documents history